

RECEIVED

JAN 25 1988

ORTH 518

GROUP 120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael P. Wachter et al.

Serial No.: 42,661

Art Unit: 121

Filed : April 29, 1987

Examiner: K. Briscoe

For : PHARMACOLOGICALLY ACTIVE
1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES AND METHOD
FOR SYNTHESIZING THE SAME

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

deposited with the United States Postal Service as
first class mail in an envelope addressed to: Commis-
sioner of Patents and Trademarks, Washington, D. C.

20231, on December 23, 1987
(Date of Deposit)

BENJAMIN F. LAMBERT
Name of applicant, assignee, or
Registered Representative

Benjamin F. Lambert
(Signature)

December 23, 1987
(Date of Signature)

FEE LETTER

Dear Sir:

Transmitted herewith is a Terminal Disclaimer in the
above-identified patent application.

Please charge the Terminal Disclaimer fee to Johnson
& Johnson Deposit Account No. 10-750.

Please charge any additional fees or credit
overpayment to Deposit Account No. 10-750. A duplicate copy
of this letter is enclosed.

Respectfully submitted,

Benjamin F. Lambert

Benjamin F. Lambert
Reg. No. 24,818
Attorney for Applicant

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(201) 524-5594

December 23, 1987

RECEIVED

JAN 25 1988

ORTH 518

GROUP 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael P. Wachter et al.

Serial No.: 42,661

Art Unit: 121

Filed : April 29, 1987

Examiner: K. Briscoe

For : PHARMACOLOGICALLY ACTIVE
1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES AND METHOD
FOR SYNTHESIZING THE SAME

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to: Commis-
sioner of Patents and Trademarks, Washington, D.C.
20231, on December 23, 1987
(Date of Deposit)

BENJAMIN F. LAMBERT
Name of applicant, assignee, or
Registered Representative
Benjamin F. Lambert
(Signature)
December 23, 1987
(Date of Signature)

COMMUNICATION

Dear Sir:

Submitted herewith is a Terminal Disclaimer which on its face conforms to 37 CFR 1.321(b). The submission of the Terminal Disclaimer is believed to overcome all of the rejections and objections to claims 1-30 of Serial No. 42,661 predicated on double patenting.

The Terminal Disclaimer is being submitted by the Assigned of the instant application, Ortho Pharmaceutical Corporation, as evidenced by the copy of the Assignment appended to the Terminal Disclaimer. The original Assignment was recorded in the Patent and Trademark Office on April 29, 1987.

Respectfully submitted,

Benjamin F. Lambert
Benjamin F. Lambert
Reg. No. 24,818
Attorney for Applicant

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(201) 524-5594
December 23, 1987

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael P. Wachter et al. **RECEIVED**
 Serial No. : 42,661 Art Unit: 121
 Filed : April 29, 1987 **JAN 25 1988**
 Examiner: K. Briscoe
 For : PHARMACOLOGICALLY ACTIVE **GROUP 120**
 1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES AND
 METHOD FOR SYNTHESIZING THE SAME


I hereby certify that this correspondence is being
 deposited with the United States Postal Service as
 first class mail in an envelope addressed to: Commis-
 sioner of Patents and Trademarks, Washington, D. C.

20231, on December 23, 1987
 (Date of Deposit)

BENJAMIN F. LAMBERT
 Name of applicant, assignee, or
 Registered Representative

Benjamin F. Lambert
 (Signature)
December 23, 1987
 (Date of Signature)

Hon. Commissioner of Patents and Trademarks
 Washington, D.C. 20231

TERMINAL DISCLAIMER

Dear Sir:


Your petitioner, Ortho Pharmaceutical Corporation,
 having its principal office in the city of Raritan, in the
 County of Somerset, State of New Jersey, represents that it is
 the Assignee of the entire right, title and interest to the
 subject matter disclosed in the above identified application as
 evidenced by an Assignment executed by the inventors of the
 application on April 28, 1987. The instant application bears
 Serial No. 42,661 and was filed on April 29, 1987 as a
 continuation-in-part of application Serial No. 867,996, filed
 May 29, 1986. A true copy of the Assignment executed by the
 inventors is appended hereto for ease of reference.

Your petitioner, Ortho Pharmaceutical Corporation, hereby disclaims, under the provisions of 35 USC 253, the terminal part of any patent granted on application Serial No. 42,661 which would extend beyond the expiration date of any patent granted on Serial No. 867,996 and hereby agrees that any patent so granted on application Serial No. 42,661 shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on Serial No. 867,996, this agreement to run with any patent granted on application Serial No. 42,661 and to be binding upon the grantee, its successors or assigns.

The Terminal Disclaimer fee is submitted herewith by way of a Charge Letter Authorization (in duplicate).

Signed at New Brunswick, New Jersey, this 23rd day of December, 1987.

ORTHO PHARMACEUTICAL CORPORATION


Benjamin F. Lambert
Assistant Secretary

Attachment